Comparison · NCT02771977-4618655e
Drug-specific Alert vs Usual Care: Percentage of Patients With Progression of AKI OR Dialysis OR Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Drug-specific Alert vs Usual Care: Percentage of Patients With Progression of AKI OR Dialysis OR Death. Trial comparisons, record NCT02771977-4618655e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02771977-4618655e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.231 | 0.215 | 0.248 | wilson | |
| Risk in group 2 | 0.253 | 0.236 | 0.27 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0217 | -0.0453 | 0.00187 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.914 | 0.829 | 1.01 | log | |
| Odds ratio, group 1 over group 2 | 0.888 | 0.781 | 1.01 | log | |
| Number needed to treat, for one fewer participant with the outcome on Drug-specific Alert than on Usual Care | 46 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: usual care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Drug-specific Alert | A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.~Drug-specific alert: A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired. | 585 | 2,532 | OG001 |
| Group 2 | Usual Care | No alert will be fired. | 639 | 2,528 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percentage of Patients With Progression of AKI OR Dialysis OR Death
- Description
Progression of AKI is defined by an increase in KDIGO creatinine stage from time of randomization to the present. Dialysis is defined by the receipt of hemodialysis, continuous renal replacement therapy or peritoneal dialysis. Isolated ultrafiltration treatments will not be included. Mortality will be determined from hospital records.
- Time frame
- 14 days from Randomization
- Population
Source ClinicalTrials.gov
Trial
- Title
- Drug-Targeted Alerts for Acute Kidney Injury
- NCT number
- NCT02771977
- Phases
- NA
- Conditions
- Acute Kidney Injury
- Interventions
- Drug-specific alert
- Lead sponsor
- Yale University
- Results first posted
- 2023-06-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02771977?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02771977-4618655e